2021 DORIS definition of remission in SLE: final recommendations from an international task force.
Ward, Michael M
Clarke, Ann Elaine
van Leeuw, Bernadette
Olesinska, Marzena Helena
Lupus Sci Med
MetadataShow full item record
van Vollenhoven, R. F., Bertsias, G., Doria, A., Isenberg, D., Morand, E., Petri, M. A., Pons-Estel, B. A., et al. (2021). 2021 DORIS definition of remission in SLE: final recommendations from an international task force.. Lupus Sci Med, 8 (1), e000538-e000538. https://doi.org/10.1136/lupus-2021-000538
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
healthcare, lupus erythematosus, outcome assessment, systemic, therapeutics
External DOI: https://doi.org/10.1136/lupus-2021-000538
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333612
Attribution-NonCommercial 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc/4.0/